ADAMTS13 deficiency clinical scoring systems
PLASMIC score and French score
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening form of thrombotic microangiopathy, characterized by the deficiency of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13). PLASMIC and French scores are risk assessment models used to predict the likelihood of severe ADAMTS13 deficiency based on clinical features and relatively simple laboratory tests, with the goal of facilitating urgent plasma replacement therapy.<br />PLASMIC score is based on the combination of 7 variables: platelet count, combined hemolysis variable, MCV (mean corpuscular volume), INR (international normalized ratio), serum creatinine, the history of cancer in the preceding year and the history of solid-organ or stem cell transplant. The French score is based on 3 variables: platelet count, serum creatinine and positive ANA (antinuclear antibodies). The resulting scores stratify the patients into low, intermediate and high risk of severe ADAMTS13 deficiency.<br />Both models have been externally validated and are recommended by the International Society on Thrombosis and Haemostasis (ISTH) guidelines for the diagnosis of thrombotic thrombocytopenic purpura.
sPESI — Απλοποιημένος δείκτης βαρύτητας PE
Εκτίμηση 30ήμερης θνητότητας σε οξεία πνευμονική εμβολή — sPESI κλίμακα βάσει ESC
The Simplified Pulmonary Embolism Severity Index (PESI) was developed to estimate 30-day mortality in patients with acute PE. It uses objective clinical items to produce a risk stratification score. The simplified PESI has similar prognostic accuracy and clinical utility and greater ease of use compared with the original PESI. It is based on 6 simple patient characteristics that were independently associated with mortality and stratifies patients with pulmonary embolism into two severity classes.
